Invega Sustenna Injection 100 mg contains Paliperidone Palmitate, a long-acting atypical antipsychotic specifically formulated for the treatment and maintenance of schizophrenia and schizoaffective disorder in adults. Paliperidone, the primary active metabolite of risperidone, acts on dopamine D2 and serotonin 5-HT2A receptors in the brain to restore neurotransmitter balance. This modulation helps reduce psychotic symptoms, improve thought processes, and stabilize mood and behavior in patients with chronic psychotic conditions.

Invega Sustenna is a monthly intramuscular injection, designed to maintain consistent therapeutic drug levels over extended periods. This long-acting formulation reduces the need for daily oral medication, thereby enhancing patient adherence, reducing relapse rates, and providing a reliable treatment option for patients who struggle with regular oral dosing. The prefilled syringe allows for accurate dosing and convenient administration under medical supervision.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Invega Sustenna Injection 100 mg is indicated for:

• Treatment and maintenance therapy of schizophrenia in adults

• Management of schizoaffective disorder as part of a comprehensive treatment plan

• Prevention of relapse in patients stabilized on paliperidone or risperidone therapy

This injectable formulation is particularly suitable for patients who have difficulty adhering to daily oral antipsychotic regimens and for long-term maintenance therapy to ensure symptom stability.

Dosage and Administration

• The recommended initiation regimen is 150 mg on Day 1 followed by 100 mg on Day 8, both administered via intramuscular injection into the deltoid muscle

• Maintenance dose is 100 mg once monthly, administered intramuscularly in either the deltoid or gluteal muscle

• Dose adjustments may be made based on clinical response, tolerability, and individual patient needs

• Administration should be performed by a trained healthcare professional using proper intramuscular injection techniques

Patients should be monitored for symptom improvement, adverse reactions, and potential extrapyramidal side effects throughout therapy.

Precautions and Warnings

• Use with caution in patients with a history of cardiovascular disorders, including QT prolongation, arrhythmias, or ischemic heart disease

• Monitor for neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension, and metabolic changes such as weight gain or hyperglycemia

• Elderly patients with dementia-related psychosis have an increased risk of mortality; Invega Sustenna is not approved for this population

• Avoid abrupt discontinuation to prevent relapse or exacerbation of symptoms

• Periodic monitoring of metabolic parameters, prolactin levels, and neurological status is recommended

Patients should immediately report symptoms such as dizziness, fainting, unusual movements, or severe allergic reactions.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Invega Sustenna Injection 100 mg is generally well tolerated. Common side effects include:

• Pain, redness, or swelling at the injection site

• Dizziness or somnolence

• Weight gain or appetite changes

• Extrapyramidal symptoms such as tremor, rigidity, or involuntary movements

• Elevated prolactin levels, potentially causing breast enlargement or menstrual irregularities

Rare but serious adverse effects include neuroleptic malignant syndrome, severe cardiovascular events, or severe allergic reactions, which require immediate medical attention.

Storage

Store below 30°C, protected from light, and do not freeze. Keep the prefilled syringe in the original packaging until use and out of reach of children.

Invega Sustenna Injection 100 mg/Prefilled Syringe (Paliperidone Palmitate) offers effective, long-term antipsychotic therapy with improved adherence, consistent symptom control, and relapse prevention, supporting the management of schizophrenia and schizoaffective disorder under proper medical supervision.